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ORIGINAL INVESTIGATION
Incremental prognostic value of global 
longitudinal strain in patients with type 2 
diabetes mellitus
Ju‑Hua Liu1,2†, Yan Chen1†, Michele Yuen3, Zhe Zhen1, Carmen Wing‑Sze Chan1, Karen Siu‑Ling Lam3,4, 
Hung‑Fat Tse1,4,5* and Kai‑Hang Yiu1,4,5*
Abstract 
Background: Patients with type 2 diabetes mellitus (T2DM) are at high risk for cardiovascular events. The aim of the 
study was to assess whether global longitudinal strain (GLS) provides prognostic value in these patients.
Methods: A total of 247 T2DM patients without history of cardiovascular complications and participated in the 
CDATS study were prospectively enrolled. Left ventricular (LV) systolic function was assessed by LV ejection fraction 
and speckle tracking derived LV systolic GLS. Diastolic function was assessed by E/E′ ratio defined as the passive 
trans‑mitral LV inflow velocity to tissue Doppler imaging velocity of the medial mitral annulus. Cardiovascular event 
included acute coronary syndrome, cerebrovascular stroke, hospitalization for heart failure and cardiovascular death.
Results: A total of 18 cardiovascular events occurred during a median follow‑up duration of 33 months. Both E/E′ 
ratio [hazard ratio (HR) 1.15, P < 0.01] and GLS (HR 1.39, P < 0.01) were independently associated with cardiovascu‑
lar events. Importantly, GLS provided incremental prognostic information in addition to clinical data, HbA1c and 
E/E′ ratio (Chi square 77.46, P = 0.04). Receiver‑operator characteristic curve analysis demonstrated that E/E′ ratio 
[area under curve (AUC) 0.66, P = 0.03] and GLS (AUC 0.72, P < 0.01) were strong predictors of cardiovascular events. 
Kaplan–Meier analysis showed that patients with E/E′ > 13.6 or GLS > −17.9 % were associated with cardiovascular 
events. The presence of either a high E/E′ ratio or an impaired GLS provides an excellent negative predictive value of 
cardiovascular events in these patients.
Conclusions: In T2DM patients with no history of cardiovascular disease, impaired GLS was associated with cardio‑
vascular events and provided incremental prognostic value.
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Background
The number of patients with type 2 diabetes mellitus 
(T2DM) is increasing rapidly in both developed and 
developing countries and will reach 380 million people by 
2025 [1]. Furthermore, approximately half of the patients 
with T2DM will die prematurely due to a cardiovascular 
disease that contributes as a major global cause of early 
mortality [2]. Therefore accurate risk stratification for 
these patients is important in order to prevent the occur-
rence of cardiovascular events.
Prior studies have demonstrated that clinical demo-
graphics and HbA1c level can help identify patients 
with T2DM at high risk for cardiovascular events [3, 
4]. In addition, the presence of diastolic dysfunction 
detected by conventional echocardiography has been 
shown to help risk stratification in these patients [5, 6]. 
Recently, the use of advanced analyzing method, namely 
global longitudinal strain (GLS) analysis derived from 
2-dimensional (2D) speckle tracking, enables the detec-
tion of subtle systolic dysfunction beyond conventional 
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echocardiography assessment [7, 8]. Whether the pres-
ence of impaired systolic strain in patients with T2DM 
with no previous history of cardiovascular complica-
tions predicts future cardiovascular events is however 
uncertain. The aim of the present study was to assess the 
incremental prognostic value of systolic GLS to predict 
for cardiovascular events in T2DM patients with no his-
tory of cardiovascular complication in addition to clinical 
data, HbA1c level and diastolic dysfunction.
Methods
Study population
A total of 333 patients with T2DM, as defined by World 
Health Organization criteria, were recruited at the 
Queen Mary Hospital, Hong Kong from March 2007 to 
March 2014. Patients who had a documented history of 
cardiovascular disease including coronary artery disease 
(n = 16), paroxysmal or chronic atrial fibrillation (n = 8), 
cerebrovascular stroke (n = 9), hospitalization for heart 
failure (n  =  7), cardiac valvular disease (n  =  5), or 
refused to participate (n = 11) were excluded. Maximum 
exercise treadmill testing was performed in the remain-
ing patients at baseline to exclude patients with potential 
ischemic heart disease (n = 20). Patients had poor echo-
cardiography image quality to analysis were also excluded 
(n = 10). The final 247 patients were enrolled for the pre-
sent study. Written informed consent was obtained from 
all participants. The study was approved by the local 
institutional review board of the Hong Kong West Clus-
ter and was conducted according to the Declaration of 
Helsinki. This study is part of the Chinese Diabetic Heart 
Study (CDATS) to evaluate cardiovascular manifestation 
in Chinese patients with T2DM, an attempt to evalu-
ate the pathophysiology and potential therapies in these 
patients [9].
Study protocol
All patients underwent a complete physical examination 
and an interview to establish baseline characteristics. 
Blood pressure was measured after patients were rested 
for at least 5 min. Smoking status was recorded as posi-
tive if patients had smoked (ever or current). BMI was 
calculated in kg/m2. Hypertension was defined as rest-
ing systolic or diastolic blood pressure ≥140/90  mmHg 
at two different clinic visits or prescription of antihyper-
tensive medication. Data on medications were ‘retrieved 
from patients’ electronic medical record, including anti-
hypertensive and anti-diabetic medication. Fasting blood 
samples were obtained to measure hemoglobinA1c, fast-
ing glucose, total cholesterol, triglyceride, high-density 
lipoprotein cholesterol, low-density lipoprotein choles-
terol and serum creatinine levels.
Conventional echocardiography
Transthoracic echocardiographic examination was per-
formed in all patients using a commercially available 
echocardiography system (Vingmed Vivid 7, General 
Electric Vingmed Ultrasound, Milwaukee, WI, USA) with 
the patient lying in the lateral decubitus position. A 3.5-
MHz transducer was used to obtain images that were 
digitally stored in cine-loop format. Off-line analysis was 
performed using the EchoPAC version 108.1.5 (General 
Electric Vingmed, Horten, Norway). Inter-ventricular 
septal dimension at end-diastole (IVSd), relative wall 
thickness (RWT) and left ventricular mass index (LVMI) 
were assessed according to the current recommendations 
[10]. Left ventricular ejection fraction (LVEF) was deter-
mined from apical four and two-chamber views using the 
modified Simpson’s biplane method. Evaluation of LV 
diastolic function was based on the pulsed-wave Dop-
pler of mitral valve inflow. Peak velocity in early diastole 
(E-wave) and late diastole (A-wave) was measured and 
the E/A ratio was calculated. Pulsed wave tissue Doppler 
imaging was used to measure the early diastolic velocity 
(E′) with the sample volume placed at the septum annu-
lus of mitral valve. In addition, the E/E′ ratio was calcu-
lated as an estimation of LV filling pressure [11].
2D speckle tracking strain analysis
LV systolic GLS was measured from 3 apical views: 
2-chamber view (anterior and inferior walls), 4-chamber 
view (poster-septum and lateral walls) and 3-chamber 
view (anterior-septum and posterior wall). Each wall was 
subsequently divided into 3 areas (basal, mid and apical) 
and a total of 18 segmental strain curves were obtained. 
Left ventricular systolic GLS was calculated as the aver-
age value of the 3 apical strain peak values at systole.
Cardiovascular event
Cardiovascular events were defined as acute coronary 
syndrome (ACS), cerebrovascular stroke, cardiovascular 
death and hospitalization for heart failure. The definition 
of ACS was based on the presence of typical chest pain, 
elevated cardiac enzyme levels, and typical electrocardio-
gram changes [12]. Hospitalization for heart failure was 
defined as admission due to dyspnea with chest radio-
graphic evidence of pulmonary congestion and treatment 
with intravenous diuretics. Cardiovascular death was 
defined as patients who died following a stroke or heart 
failure or acute myocardial infarction. If patients had 
multiple cardiovascular events, only the first event was 
coded. In the study end points, patients with cardiovas-
cular event were followed until the first episode of car-
diovascular events, the others were followed until March 
2015 or the date of death.
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Statistical analysis
Data are expressed as mean  ±  standard deviation for 
continuous variables and frequencies or proportions 
for categorical variables. Clinical predictors of cardio-
vascular event were assessed by univariate Cox regres-
sion analysis. Independent echocardiography predictor 
of cardiovascular event was assessed by univariate and 
multivariable Cox regression analysis adjusted for age, 
gender and covariates which are significant variables 
in the clinical data. A nested Cox proportional hazard 
regression analysis was used to investigate incremental 
prognostic value of the predictors. To take into account 
the time-dependent characteristics of receiver-operating 
characteristic curves, the prognostic model was assessed 
with the receiver-operating characteristic curves. The 
optimal cutoff value was defined as the maximized value 
for the sum of sensitivity and specificity. The cumulative 
probability of cardiovascular event during the follow-up 
period was estimated using the Kaplan–Meier method 
and compared with the log-rank test. For Inter-observer 
reproducibility of echocardiographic parameters was 
assessed by intra-class correlation coefficient; 24 subjects 
were randomly chosen for this analysis. Statistical analy-
ses were performed using standard statistical computer 
software SPSS for window (Version 17.0). All P values 
reported are 2-sided for consistency and P  <  0.05 was 
considered statistically significant.
Results
Clinical data and predictors of cardiovascular events
Baseline clinical characteristics of the enrolled patients 
and predictors of cardiovascular events are shown in 
Table  1. The mean age was 60  years and there was an 
even gender distribution. A total of 18 cardiovascular 
events were recorded during a median follow-up dura-
tion of 33  months; 7 patients diagnosed with ACS, 3 
patients with hospitalizations for heart failure, 6 patients 
with cerebrovascular stroke and 2 cardiovascular deaths 
due to refractory heart failure.
Clinical predictors of cardiovascular events assessed 
by univariate Cox regression analysis were age [hazards 
ratio (HR) 1.08; 95 % confidence interval (CI) 1.03–1.13, 
P  <  0.01], history of hyperlipidemia (HR 2.96, 95  % CI 
1.0–8.37, P  =  0.04), treatment with insulin (HR 2.96, 
95 % CI 1.12–7.82, P = 0.03) and serum creatinine level 
(HR 1.01, 95 % CI 1.00–1.01, P < 0.01).
Echocardiography parameters
All patients had a preserved LVEF (all LVEF  >50  %) at 
baseline and the mean LVEF were 63.2  ±  4.5  %. Echo-
cardiography parameters associated with cardiovascular 
events were shown in Table  2. Both E/E′ ratio and GLS 
were significant associated with cardiovascular events in 
univariate Cox regression analysis. After adjusted Cox 
regression analysis, E/E′ ratio and GLS remained associ-
ated with cardiovascular events. No such association was 
observed in LVEF and E/A ratio, as well as parameters of 
LV geometry, including IVSd, RWT and LVMI. To exam-
ine the incremental prognostic value of the predictors, we 
performed a nested Cox proportional hazard regression 
analysis. A model based on clinical data including age, 
gender, hyperlipidemia, plasma creatinine and treatment 
with insulin was improved by HbA1c and E/E′ ratio. The 
addition of GLS to the model provided incremental prog-
nostic information beyond clinical data, HbA1c and E/E′ 
ratio (Fig. 1).
Table 1 Clinical data of patients and Cox regression analy-
sis in association with cardiovascular events
Italic values indicate statistically significant with P < 0.05
ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor 
antagonist, CI confidence interval, DBP diastolic blood pressure, FBG fasting 
blood glucose, HbA1c hemoglobinA1c, HDL high-density lipoprotein cholesterol, 
HR hazard ratio, LDL low-density lipoprotein cholesterol, SBP systolic blood 
pressure, TC total cholesterol, TG triglyceride
Variable Total (n = 247) B HR (95 % CI) P
Demographic data
 Age, years 59.8 ± 9.5 0.07 1.08 (1.03–1.13) <0.01
 Female, n (%) 120 (48.6) 0.77 2.15 (0.80–5.76) 0.13
 Body mass index, 
kg/m2
26.2 ± 4.8 −0.08 0.93 (0.82–1.04) 0.20
 SBP (mmHg) 136.3 ± 18.7 −0.001 1.00 (0.97–1.03) 0.93
 DBP (mmHg) 79.1 ± 8.8 −0.03 0.97 (0.92–1.03) 0.33
Medical history
 Diabetes durations, 
years
13.5 ± 8.2 0.03 1.03 (0.99–1.08) 0.15
 Hypertension, n (%) 186 (75.3) 1.06 2.90 (0.67–12.6) 0.16
 Hyperlipidemia, 
n (%)
130 (52.6) 1.09 2.96 (1.05–8.37) 0.04
 Smoking, n (%) 55 (22.3) 0.17 1.19 (0.39–3.64) 0.76
Medication
 ACEI/ARB, n (%) 134 (54.3) 0.39 1.48 (0.58–3.78) 0.42
 Calcium channel 
blocker, n (%)
105 (42.5) 0.57 1.76 (0.69–4.47) 0.23
 B‑blocker, n (%) 55 (22.3) 0.10 1.11 (0.36–3.37) 0.86
 Biguanides, n (%) 210 (85.0) −0.23 0.80 (0.28–2.30) 0.67
 Insulin (%) 110 (44.5) 1.09 2.96 (1.12–7.82) 0.03
Blood chemistry
 FBG (mmol/L) 8.0 ± 2.5 −0.26 0.77 (0.58–1.02) 0.06
 HbA1c (%) 7.8 ± 1.4 −0.30 0.74 (0.49–1.13) 0.16
 TG (mmol/L) 1.4 ± 1.0 −0.24 0.79 (0.43–1.45) 0.44
 TC (mmol/L) 4.5 ± 0.8 −0.16 0.86 (0.50–1.48) 0.58
 HDL (mmol/L) 1.3 ± 0.4 0.81 2.25 (0.79–6.37) 0.13
 LDL (mmol/L) 2.5 ± 0.7 −0.49 0.61 (0.29–1.30) 0.20
 Creatinine 
(mmol/L)
80.2 ± 39.2 0.01 1.01 (1.00–1.01) <0.01
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E/E′ ratio and GLS are associated with cardiovascular 
events
The receiver-operating characteristic curve was gener-
ated to determine the accuracy of E/E′ ratio and GLS 
in association with cardiovascular events. As shown in 
Fig.  2, E/E′ ratio and GLS were significantly associated 
with cardiovascular events. Kaplan–Meier analysis dem-
onstrated that E/E′  >  13.6 or GLS  > −17.9  % was asso-
ciated with cardiovascular events (Fig. 3). In the present 
study, a total of 10.5 % (n = 26) patients had a E/E′ > 13.6 
and 42.5 % (n =  105) patients had a GLS > −17.9 %. A 
cut-off value of 13.6 for E/E′ ratio provided a sensitiv-
ity of 44.4  % and specificity of 92.1  %, whereas a cutoff 
value of −17.9 % for GLS showed a sensitivity of 77.8 % 
and specificity of 60.3  %. A combination of  >13.6 E/E′ 
and > −17.9 % GLS had a sensitivity of 38.9 %, a specific-
ity of 97.4 %, a positive predictive value of 53.8 %, and a 
negative predictive value of 95.3 %. Importantly, the pres-
ence of either >13.6 E/E′ or > −17.9 % GLS had a sensitiv-
ity of 83.3 %, a specificity of 55.0 %, a positive predictive 
value of 12.7 %, and a negative predictive value of 97.7 %.
Table 2 Adjusted Cox regression analysis of  individual 
echocardiography parameters for cardiovascular events
Italic values indicate statistically significant with P < 0.05
Abbreviations: Similar to Table 1, E/A ratio the ratio of peak mitral flow velocity 
in early and late at diastole, E/E′ ratio the ratio of early peak mitral inflow 
velocity to early myocardial velocity of mitral annulus at diastole, GLS global 
longitudinal stain, IVSd Inter-ventricular septal dimension at end-diastole, LVEF 
left ventricular ejection fraction, LVMI left ventricular mass index, RWT relative 
wall thickness
a Clinical data includes age, gender, hyperlipidemia, plasma creatinine and 
treatment with insulin
Variable Value (n = 247) B HR (95 % CI) P
IVSd (cm) 1.13 ± 0.19
Univariate analysis 2.01 7.43 (0.66–83.7) 0.10
Adjusted clinical 
dataa
1.43 4.17 (0.31–56.8) 0.28
Adjusted clinical 
data + HbA1c
1.87 6.50 (0.47–89.5) 0.16
RWT, ratio 0.50 ± 0.09
Univariate analysis −0.47 0.63 (0.002–171.5) 0.87
Adjusted clinical 
dataa
−1.25 0.29 (0.001–89.3) 0.67
Adjusted clinical 
data + HbA1c
0.87 2.39 (0.01–783.1) 0.77
LVMI (g/m2) 100.7 ± 24.7
Univariate analysis 0.02 1.02 (1.00–1.03) 0.07
Adjusted clinical 
dataa
0.01 1.01 (0.99–1.04) 0.29
Adjusted clinical 
data + HbA1c
0.01 1.01 (0.99–1.04) 0.27
LVEF (%) 63.2 ± 4.5
Univariate analysis −0.08 0.92 (0.83–1.02) 0.13
Adjusted clinical 
dataa
−0.07 0.94 (0.85–1.04) 0.19
Adjusted clinical 
data + HbA1c
−0.08 0.93 (0.84–1.02) 0.11
E/A ratio 0.94 ± 0.31
Univariate analysis −2.51 0.08 (0.01–0.98) 0.05
Adjusted clinical 
dataa
−1.05 0.35 (0.02–6.09) 0.47
Adjusted clinical 
data + HbA1c
−1.62 0.20 (0.01–4.04) 0.29
E/E′ ratio 10.4 ± 4.5
Univariate analysis 0.15 1.16 (1.10–1.22) <0.01
Adjusted clinical 
dataa
0.14 1.16 (1.09–1.23) <0.01
Adjusted clinical 
data + HbA1c
0.14 1.15 (1.08–1.22) <0.01
GLS (%) −18.1 ± 2.4
Univariate analysis 0.27 1.31 (1.10–1.56) <0.01
Adjusted clinical 
dataa
0.29 1.35 (1.10–1.65) <0.01
Adjusted clinical 
data + HbA1c
0.33 1.39 (1.14–1.70) <0.01
Fig. 1 Change in model Chi square with addition of HbA1c, E/E′ 
ratio and GLS to clinical data (including age, gender, hyperlipidemia, 
plasma creatinine and treatment with insulin). E/E′ ratio the ratio of 
early peak mitral inflow velocity to early myocardial velocity of mitral 
annulus at diastole, GLS global longitudinal stain, HbA1c hemoglobi‑
nA1c
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Reproducibility of E/E′ and GLS
Variability was measured for left ventricular E/E′ and 
GLS. Intra-class correlation coefficient showed good 
inter-observer agreement with non-significant differ-
ences. Intra-observer coefficient was 0.91 for E/E′ and 
0.99 for GLS.
Discussion
The present study demonstrates that GLS measured by 
2D speckle tracking derived strain is independently asso-
ciated with cardiovascular events in T2DM patients with 
no history of cardiovascular complications. Importantly, 
assessment of GLS provides incremental prognostic 
value to clinical data, HbA1c level and diastolic function 
assessed by E/E′ ratio in those patients.
Association between LV diastolic dysfunction 
and cardiovascular events
To better risk stratify patients with T2DM, prior studies 
have developed scoring systems based on HbA1c levels 
and clinical demographics [13–15]. Results have shown 
that patients with severe disease status were more fre-
quent to develop cardiovascular events. Similarly, the 
present study demonstrated that age, medical history of 
hyperlipidemia, treatment with insulin and serum creati-
nine levels were significantly associated with cardiovas-
cular events. Nonetheless, these scoring systems provide 
modest prognostic value and tend to overestimate the 
overall risk [16–18]. As a result, additional methods to 
improve risk stratification in these patients are required. 
Echocardiography is a non-invasive modality to assess 
cardiac function. Diastolic dysfunction, a common find-
ing in patients with T2DM that can be readily assessed 
by echocardiography [19], is closely associated with the 
state of insulin resistance [20], impaired fasting glucose 
[21] and medical history of coronary microvascular dis-
ease [22]. In particular, an impaired diastolic function 
defined by an E/E′ ratio of >15 has been shown to be asso-
ciated with 1.08–1.61 fold increased risk of cardiovascu-
lar events [5]. In patients with T2DM with no history of 
cardiovascular complications, E/E′ ratio tends only to be 
mildly elevated [7, 23]. Accordingly, only a small fraction 
of these patients will reach an E/E′ ratio of  >15. In the 
present study, the E/E′ ratio was only mildly elevated and 
only 14 (5.7 %) patients had an E/E′ ratio of >15. Nonethe-
less, E/E′ ratio remains significantly associated with car-
diovascular events in the present cohort of patients with 
no history of cardiovascular complications. Further, ROC 
demonstrated that a cut-off value of 13.6 for E/E′ provides 
a reasonable sensitivity to predict cardiovascular events. 
This finding thus supports the assessment of diastolic dys-
function to improve risk stratification, even in patients 
who have not developed cardiovascular complication.
Association between LV systolic dysfunction 
and cardiovascular events
Strain analysis derived from speckle tracking enables 
detection of subclinical myocardial systolic dysfunction 
Fig. 2 Receiver‑operating characteristic curves for prediction of 
cardiovascular events in patients with type 2 diabetes mellitus using 
E/E′ ratio and GLS. Abbreviations: Similar to Fig. 1
Fig. 3 Kaplan–Meier analysis of cardiovascular event‑free survival 
according to GLS > −17.9 % compared with GLS ≤ −17.9 % (Log 
rank χ2 = 6.52 P = 0.01), and E/E > 13.6 compared with E/E′ ≤ 13.6 
(Log rank χ2 = 26.73 P < 0.01). Abbreviations: Similar to Fig. 1
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beyond conventional LVEF assessment. Studies have 
demonstrated that impaired GLS was observed not only 
in T2DM patients with no history of cardiovascular com-
plications but also in asymptomatic T2DM patients even 
with normotensive [7, 23, 24], whist coexistent of diabetic 
complications, hypertension, hypertriglyceridemia and 
overweight or obesity resulted in further damage to myo-
cardial contractility [25–27]. Nonetheless, limited studies 
have evaluated the prognostic value of GLS in patients 
with T2DM. In a study involving 406 patients, GLS did 
not demonstrate independent prognostic value [5]. While 
in another study that included only patients who had no 
history of cardiovascular complication, GLS was able to 
predict cardiovascular events, a finding confirmed by the 
present study [23]. Importantly, the current study is the 
first to demonstrate the incremental prognostic value of 
GLS beyond clinical data, HbA1c and diastolic function. 
In particular, a GLS of > −17.9 % provides a sensitivity of 
77.8 %. This finding thus highlights the usefulness of GLS 
assessment in patients with T2DM.
Clinical implication
The current recommendation of cardiovascular screen-
ing for diabetic patients does not include the routine 
use of echocardiography to detect diastolic or systolic 
dysfunction [28]. Indeed, both diastolic and systolic dys-
function is common in patients with T2DM, even before 
they developed cardiovascular complication [7, 29]. The 
present study demonstrates that the use of echocardi-
ography assessment, particularly diastolic function and 
systolic strain analysis, provides incremental prognos-
tic value to routine clinical parameters. Importantly, 
the presence of either E/E′ > 13.6 or GLS > −17.9 % has 
a high negative predictive value (97.7 %) and may iden-
tify patients who are at low risk of cardiovascular events. 
The present finding thus supports the value of echo-
cardiography assessment to identify low risk patients, 
before the development of cardiovascular complication 
and warrants consideration to be performed routinely. 
Nonetheless, it is important to note that the low speci-
ficity of either of these values suggests the limited role 
to detect high-risk patients. Clinician should therefore 
consider additional parameters, in addition to E/E′ and 
GLS, to accurately detect those who are at high-risk for 
future cardiovascular events. It is worthy of note that the 
AUC under the ROC of E/E′ and GLS was 66 and 72 %, 
respectively. Although significant, these parameters 
only provide moderate discriminating capacity and the 
overall risk stratification in patients with T2DM should 
combine with other risk stratification parameters. Fur-
thermore, a total of 13 patients with both E/E′  >  13.6 
and GLS > −17.9 %, 2 (15.4 %) patients developed IHD, 
2 (15.4 %) patients developed HF and 2 (15.4 %) patients 
died due to refractory heart failure during follow-up. The 
potential value of cardiac computed tomography or coro-
nary angiography assessment to detect significant coro-
nary artery disease in these patients would nonetheless 
require further study.
Limitation
The current study did not perform coronary artery imag-
ing in all patients to rule out silent ischemia or asymp-
tomatic coronary artery disease. Nonetheless, patients 
in the present study had no history of myocardial infarc-
tion as supported by preserved LVEF and negative stress 
test in all patients. Indeed, we believe that the present 
study population may better represent patients that are 
encountered in clinical setting where coronary artery 
assessment are not routinely performed according to the 
current recommendation [28]. Along the same line, the 
current cohort did not include patients who had already 
developed cardiovascular complications and the present 
findings thus need verification for this group of patients 
by future studies. Furthermore, data on left atrial geom-
etry and function was not included. A larger study should 
be performed not only to better define the cut-off value of 
both diastolic and systolic function but also to assess the 
prognostic value of left atrial size and function. Finally, 
potential limitations of echocardiography assessment 
are dependent on high quality of images and appropriate 
imaging settings, which can be influenced by medical his-
tory of morbidity or pulmonary disease.
Conclusions
The present study demonstrates that impaired GLS was 
associated with cardiovascular events in T2DM patients 
with no history of cardiovascular complications. Impor-
tantly, GLS provides incremental prognostic value to 
clinical demographics, HbA1c and diastolic function in 
these patients. Further, an E/E′ > 13.6 or GLS > −17.9 % 
provided an excellent negative predictive value for car-
diovascular events. Addressing these parameters by 
echocardiography may improve risk stratification in 
patients with T2DM with no history of cardiovascular 
complications.
Abbreviations
A‑wave: peak mitral inflow velocity in late at diastole; E‑wave: peak mitral 
inflow velocity in early at diastole; E′: the early myocardial velocity of medial 
mitral annulus at diastole; GLS: global longitudinal stain; LVEF: left ventricular 
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